A randomized, controlled, open-label, phase 2 study of Cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma

  • Alamgeer, Muhammad (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date14/01/20 → 13/01/25
View all
View less

Keywords

  • clinical trial
  • phase 2 study
  • treatment efficacy
  • cell carcinoma